Telesis Bio Inc. announced continued expansion of the BioXp Select product line, releasing two novel kits to enable DNA amplification and scale-up. The BioXp Select DNA Cloning and Amplification Kit and the BioXp Select Plasmid Amplification Kit enable on-demand and automated synthesis and amplification of transfection-scale DNA beginning from the customers own DNA fragments or plasmid DNA, overnight and at the push of a button. This is expected to enable researchers to optimize their discovery workflows by reducing the time and steps for cloning and scale-up of DNA required for their testing and analysis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.99 USD | +13.41% |
|
+31.32% | -30.52% |
May. 09 | Earnings Flash (TBIO) TELESIS BIO Reports Q1 Revenue $3.4M | MT |
May. 09 | Telesis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.52% | 8.4M | |
+7.77% | 218B | |
+10.16% | 189B | |
+26.21% | 151B | |
+32.78% | 113B | |
+1.98% | 64.02B | |
+14.48% | 52.6B | |
+2.92% | 49.85B | |
-6.60% | 37.89B | |
-1.07% | 34.92B |
- Stock Market
- Equities
- TBIO Stock
- News Telesis Bio, Inc.
- Telesis Bio Inc. Releases Bioxp® Select Kits to Enable DNA Amplification and Scale-Up